medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2014-19-80-88medsovet-812Research ArticleПрактикаPracticeОригинальный и генерические тамсулозины: есть ли разница?Original and generic Tamsulosin: is there a difference?ЗыряновС. К.ZyryanovSKnoemail@neicon.ruБелоусовЮ. Б.BelousovYBnoemail@neicon.ruКамаевА. В.KamayevAVnoemail@neicon.ruКривобородовГ. Г.KrivoborodovGGnoemail@neicon.ruГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииРоссияPirogov Russian National Research Medical University, Russia’s Ministry of HealthRussian FederationНациональное агентство клинической фармакологии и фармации, МоскваРоссияNational Agency for Clinical Pharmacology and Pharmacy, MoscowRussian Federation2014301220140198088Copyright © Зырянов С.К., Белоусов Ю.Б., Камаев А.В., Кривобородов Г.Г., 20142014Зырянов С.К., Белоусов Ю.Б., Камаев А.В., Кривобородов Г.Г.Zyryanov S., Belousov Y., Камаев А.В., Krivoborodov G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/812

Антагонисты а1-адренорецепторов (а-адреноблокаторы) являются одними из самых эффективных препаратов для лечения пациентов с симптомами нижних мочевых путей (СНМП), вызванными доброкачественной гиперплазией предстательной железы (ДГПЖ; СНМП/ ДГПЖ). На основании анализа исходов лечения эти лекарственные средства были признаны препаратами выбора для терапии ДГПЖ Американской урологической ассоциацией [1].

Antagonists of α1-adrenergic receptors (α-blockers) are among the most effective drugs for the treatment of patients with lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH; LUTS/BPH). Based on the results of treatment outcome analysis, the American Urological Association acknowledged these drugs as drugs of choice for the treatment of BPH [1].

а-адреноблокаторытамсулозинОмникфармацевтическая эквивалентностьα-blockerstamsulosinOmniquepharmaceutical equivalenceReferencesRoehrborn CG, Mc Connel J, Barry MJ et al. Guideline on the Management of Benign Prostatic Hypertrophy. AUA website: http://www.auanet.org/content/guidelines-and- quality-care/clinical-guidelines/main-reports/bph-management/preface_toc.pdf.Roehrborn CG, Mc Connel J, Barry MJ et al. Guideline on the Management of Benign Prostatic Hypertrophy. AUA website: http://www.auanet.org/content/guidelines-and- quality-care/clinical-guidelines/main-reports/bph-management/preface_toc.pdf.Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest updated on a1-adrenoceptor antagonists. BJUInt., 2005, 95 (Suppl. 4): 29-36.Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest updated on a1-adrenoceptor antagonists. BJUInt., 2005, 95 (Suppl. 4): 29-36.van Dijk MM, de la Rosette JJMCH, Michel MC. Tamsulosin - modifi ed-release and oral-controlled absorption system formulation in the treatment of benign prostatic hyperplasia. Therapy, 2006, 3: 237-246.van Dijk MM, de la Rosette JJMCH, Michel MC. Tamsulosin - modifi ed-release and oral-controlled absorption system formulation in the treatment of benign prostatic hyperplasia. Therapy, 2006, 3: 237-246.McConell ID, Roeborn CG, Bautista OM et al. The long-term effect of doxazozine, finasteride, and combination therapy on the clinical progression of bening prostatic hyperplasia. N Engl. J. Med.,, 2003, 349: 2387-98.McConell ID, Roeborn CG, Bautista OM et al. The long-term effect of doxazozine, finasteride, and combination therapy on the clinical progression of bening prostatic hyperplasia. N Engl. J. Med.,, 2003, 349: 2387-98.Lepor H. Long-term efficacy and safety of terazosin in patients with bening prostatic hyperplasia. Terazosin Research Group. Urology, 1995, 45: 406-13.Lepor H. Long-term efficacy and safety of terazosin in patients with bening prostatic hyperplasia. Terazosin Research Group. Urology, 1995, 45: 406-13.Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of a-adrenergic blockers for symptoms related to bening prostatic hyperplasia. Int. J. Clin. Pract, 2008, 62 (10): 1547-1559.Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of a-adrenergic blockers for symptoms related to bening prostatic hyperplasia. Int. J. Clin. Pract, 2008, 62 (10): 1547-1559.www.grls.rosminzdrav.ruwww.grls.rosminzdrav.ruDivision of Drug Management and Policies. Summary of Counterfeit Drug Database as of April 1999 [unpublished manuscript]. Geneva, Switzerland: World Health Organization; 1999.Division of Drug Management and Policies. Summary of Counterfeit Drug Database as of April 1999 [unpublished manuscript]. Geneva, Switzerland: World Health Organization; 1999.Пушкарь Д.Ю., Белоусов Ю.Б., Раснер П.И., Духанин А.С., Манешина О.А. Исследование степени уроселективности препарата Омник (тамсулозин) и его генерических аналогов. Consilium medicum, 2009, 7: 3-6.Пушкарь Д.Ю., Белоусов Ю.Б., Раснер П.И., Духанин А.С., Манешина О.А. Исследование степени уроселективности препарата Омник (тамсулозин) и его генерических аналогов. Consilium medicum, 2009, 7: 3-6.

The authors declare that there are no conflicts of interest present.